NUWIQ® – Efficacy

Home » Clinical Evidence » Efficacy

POWERFUL BLEEDING CONTROL
Prophylaxis with NUWIQ Markedly Reduced Bleeding Frequency1,2

In Clinical Trials of Standard Prophylaxis with NUWIQ in Adult (N=32) and Pediatric (N=59) Patients Treated for ≥6 Months1*

ZERO

Median ABR
Spontaneous Bleeds
Adults and Children

In Adults
Median ABR for All Bleeds is 0.9

In Children
Median ABR for All Bleeds is 1.9

ABR = annualized bleeding rate

*NUWIQ prophylaxis regimen: every other day or 3 times per week for ≥ 6 months.

All Patients Experienced Fewer Bleeds with NUWIQ Prophylaxis vs On-Demand Treatment with Another FVIII Product1,2†

Patients were switched from on-demand therapy (pre-study) with another FVIII product to prophylaxis with NUWIQ.

†Based on negative binomial model.

EFFECTIVE BLEEDING RESOLUTION
On-Demand Treatment with NUWIQ Readily Controlled Bleeding1

In Adult Patients Receiving On-Demand Treatment with NUWIQ3,4

N=986 bleeds evaluated

Bleeds Resolved
With 1 Infusion

Bleeds Resolved
With 1 or 2 Infusions

94% of on-demand responses to NUWIQ rated as “excellent” or “good”1

Control and Prevention of Bleeding During and After Surgery1

Thirty-three surgical procedures (N=19)

In 100% of minor surgeries hemostasis rated as "excellent"

In 92% of major surgeries hemostasis rated as "excellent" or "good"

nuwiq circles

Personalized prophylaxis has the potential to improve care and enable fewer infusions for your patient

Find out if personalized prophylaxis with NUWIQ is right for your patients.
References
  1. NUWIQ full Prescribing Information. Paramus, NJ: Octapharma; rev 2021.
  2. Data on file. Paramus, NJ: Octapharma USA, Inc; 2015.
  3. Valentino LA, et al. Haemophilia.2014;20 (Suppl. 1), 1–9.
  4. Kessler C, et al. Haemophilia. 2015;21(Suppl. 1): 1-12.